GlassScriptPhysician profile
Debra R Miller
NPI 1447255864
$11,825.23
in general payments reported to CMS, 2019-2025
64 companies · $2,081 in 2025
The $2,081 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $899 · 2021: $2,367 · 2022: $1,618 · 2023: $2,454 · 2024: $1,930 · 2025: $2,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,930 · Education: $368 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,929.78 |
| Education | $368.02 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,724.60 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $821.59 | 2019-2025 | Lynparza, Enhertu, Tagrisso |
| Seagen INC. | $770.21 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Pfizer INC. | $708.09 | 2020-2025 | |
| Genentech USA, INC. | $639.94 | 2020-2025 | Tecentriq, Venclexta, Alecensa |
| Incyte Corporation | $507.82 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Daiichi Sankyo INC. | $494.64 | 2020-2025 | Enhertu, Datroway |
| Amgen INC. | $448.22 | 2020-2024 | Evenity, Prolia, Nplate |
| Glaxosmithkline, LLC. | $354.60 | 2020-2025 | Jemperli, Ojjaara, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $300.78 | 2019-2025 | Opdivo |
| Puma Biotechnology, INC. | $262.04 | 2020-2025 | Nerlynx |
| Celgene Corporation | $258.89 | 2019-2025 | Reblozyl, Pomalyst |
| Exelixis INC. | $258.48 | 2020-2025 | Cabometyx |
| Gilead Sciences, INC. | $256.97 | 2021-2025 | Trodelvy |
| Astellas Pharma US INC | $249.91 | 2022-2025 | Padcev, Xtandi, Xospata |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $245.52 | 2020-2025 | Darzalex, Talvey, Tecvayli |
| Aveo Pharmaceuticals, INC. | $223.74 | 2024-2025 | |
| Stemline Therapeutics INC. | $204.07 | 2023-2025 | Orserdu |
| Merck Sharp & Dohme LLC | $196.15 | 2020-2025 | Keytruda, Lynparza |
| Jazz Pharmaceuticals INC. | $186.24 | 2020-2023 | |
| Array Biopharma INC | $166.70 | 2019-2025 | Braftovi, Lorbrena, Mektovi |
| Takeda Pharmaceuticals U.S.A., INC. | $149.02 | 2021-2025 | Ninlaro, Fruzaqla, Iclusig |
| Eisai INC. | $145.16 | 2021-2025 | |
| Abbvie INC. | $141.86 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $132.45 | 2024 | Rybrevant |
| Ipsen Biopharmaceuticals, INC | $120.14 | 2021-2024 | Onivyde |
| Clovis Oncology, INC. | $118.43 | 2019-2020 | |
| Lilly USA, LLC | $112.38 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $106.17 | 2021-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $103.57 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $96.57 | 2023-2025 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $93.50 | 2020-2023 | Imbruvica |
| Adc Therapeutics America, INC. | $88.13 | 2024-2025 | |
| Emd Serono, INC. | $83.65 | 2022 | |
| Mirati Therapeutics, INC. | $82.40 | 2023-2024 | Krazati |
| Blueprint Medicines Corporation | $70.01 | 2021-2023 | Ayvakit |
| Coherus Oncology, INC. | $67.53 | 2022-2024 | |
| Sobi, INC | $64.11 | 2024-2025 | |
| Amag Pharmaceuticals, INC. | $59.62 | 2019-2021 | |
| Tersera Therapeutics LLC | $58.66 | 2023-2024 | Xermelo, Zoladex |
| Dova Pharmaceuticals | $56.01 | 2020-2021 | |
| Kyowa Kirin, INC. | $54.96 | 2020-2021 | |
| Beigene USA, INC. | $54.80 | 2022-2024 | Brukinsa |
| Sun Pharmaceutical Industries INC. | $44.66 | 2025 | |
| Genzyme Corporation | $43.87 | 2021-2025 | |
| Heron Therapeutics, INC. | $33.31 | 2020 | |
| Caris Mpi, INC. | $25.68 | 2025 | Mi Cancer Seek |
| Cti Biopharma Corp. | $25.39 | 2023 | Vonjo |
| Pharmaessentia USA Corporation | $24.85 | 2024 | Besremi |
| Immunogen, INC. | $24.36 | 2023 | Elahere |
| Pharmaand Gmbh | $23.92 | 2025 | Rubraca |
| Tolmar, INC. | $23.92 | 2025 | Eligard, Rubraca |
| Adaptive Biotechnologies Corporation | $23.07 | 2025 | Clonoseq |
| Geron Corporation | $22.38 | 2025 | Rytelo |
| Karyopharm Therapeutics INC. | $20.36 | 2025 | Xpovio |
| Myriad Genetic Laboratories, INC. | $19.28 | 2024 | Myrisk |
| Legend Biotech USA INC. | $18.14 | 2025 | Carvykti |
| Acrotech Biopharma INC. | $18.04 | 2025 | Beleodaq |
| Agios Pharmaceuticals, INC. | $18.00 | 2023 | Pyrukynd |
| Epizyme, INC. | $16.72 | 2021 | |
| Tactile Systems Technology INC | $16.54 | 2025 | Nimbl, Flexitouch Plus |
| Deciphera Pharmaceuticals INC. | $16.49 | 2023 | Qinlock |
| Fortovia Therapeutics, INC. | $15.48 | 2019 | |
| Sanofi Pasteur INC. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.